Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)

Quizartinib is the first FLT3 inhibitor to demonstrate improved overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations, a very aggressive form of the disease associated with poo... Biopharmaceuticals, Oncology Daiichi Sankyo Company, quizartinib, acute myeloid leukemia, FLT3 inhibitor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news